<- Go Home
Kezar Life Sciences, Inc.
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company’s lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Market Cap
$53.9M
Volume
78.3K
Cash and Equivalents
$66.2M
EBITDA
-$40.7M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
-$33.8M
Profit Margin
N/A
52 Week High
$7.55
52 Week Low
$3.53
Dividend
N/A
Price / Book Value
0.82
Price / Earnings
-1.18
Price / Tangible Book Value
0.82
Enterprise Value
-$11.0M
Enterprise Value / EBITDA
0.29
Operating Income
-$41.4M
Return on Equity
53.75%
Return on Assets
-26.77
Cash and Short Term Investments
$66.2M
Debt
$1.4M
Equity
$65.2M
Revenue
N/A
Unlevered FCF
-$18.3M
Sector
Biotechnology
Category
N/A